A. Cutrell

发表

HIV prevention trial design in an era of effective pre-exposure prophylaxis

R. D. Meyer, D. Glidden, D. Dunn, 2017, HIV clinical trials.

A Double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects

R. Hamatake, Z. Hong, M. Rodríguez-Torres, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48‐week data from a randomized, double‐blind trial

B. Clotet, C. Katlama, E. Bernasconi, 2001, HIV medicine.

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy

C. Katlama, S. Staszewski, V. Miller, 2000, AIDS.

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min

C. Gilks, A. Walker, D. Gibb, 2019, PloS one.

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

S. Hammer, J. Montaner, D. Cooper, 2001, JAMA.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

S. Swindells, C. Orrell, Kimberly Smith, 2020, The Lancet.

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

S. Swindells, S. Oka, C. Orkin, 2020, Journal of acquired immune deficiency syndromes.

Risk factor analysis of hypersensitivity reactions to abacavir.

S. Hetherington, W. Symonds, A. Cutrell, 2002, Clinical therapeutics.

A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.

R. Nelson, J. Church, J. Sleasman, 2001, Pediatrics.

Mutations in HIV-1 Reverse Transcriptase during Therapy with Abacavir, Lamivudine and Zidovudine in HIV-1-Infected Adults with No Prior Antiretroviral Therapy

M. Fischl, N. Clumeck, M. Ait-Khaled, 2002, Antiviral therapy.

A dose‐ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment‐naive subjects

T. Harrer, C. Katlama, S. Staszewski, 1998, AIDS.

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.

H. Stellbrink, C. Orkin, Kimberly Smith, 2021, The lancet. HIV.

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.

S. Oka, S. Walmsley, C. Orkin, 2020, The New England journal of medicine.

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

D. Kuritzkes, J. Schapiro, J. Polli, 2021, AIDS.

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

O. Naderer, G. Pearce, H. Steel, 2001, Clinical therapeutics.

Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase

R. Haubrich, M. Lederman, J. Mellors, 2000, AIDS.

Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects

D. Lapierre, L. Curtis, S. Bowlin, 2009, Journal of acquired immune deficiency syndromes.

Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir

A. Cutrell, Martha A. Moore, Jaime E. Hernandez, 2004, The Annals of pharmacotherapy.

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects

M. Marzinke, R. Landovitz, W. Spreen, 2022, British journal of clinical pharmacology.

Antiretroviral Activity and Safety of Abacavir in Combination with Selected HIV-1 Protease Inhibitors in Therapy-Naive HIV-1-Infected Adults

R. Haubrich, M. Lederman, J. Mellors, 2000, Antiviral therapy.

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.

S. Oka, C. Orkin, Kimberly Smith, 2021, The lancet. HIV.

Abacavir and the potential risk of myocardial infarction

D. Lapierre, A. Cutrell, J. Yeo, 2008, The Lancet.

The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial

B. Clotet, C. Katlama, E. Bernasconi, 2000, AIDS.

Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project

D. Glidden, V. Miller, J. Hughes, 2022, Clinical pharmacology and therapeutics.

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.

D. Kuritzkes, J. Schapiro, J. Polli, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.